ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,040.53
-0.50%
US Tech 100
20,778.00
-0.69%
다우존스 지수
44,544.66
-0.75%
Bitcoin
99,935.63
-0.73%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) 뉴스

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:NTLA
일자시간출처헤드라인심볼기업
2025/02/0106:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2025/01/2407:41Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2025/01/2221:30GlobeNewswire Inc.Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
2025/01/1021:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
2025/01/1006:00GlobeNewswire Inc.Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)NASDAQ:NTLAIntellia Therapeutics Inc
2025/01/0807:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2025/01/0807:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2025/01/0807:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2025/01/0807:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2025/01/0807:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2025/01/0706:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2025/01/0621:30GlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
2024/12/0406:01GlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
2024/11/2521:30GlobeNewswire Inc.Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with PolyneuropathyNASDAQ:NTLAIntellia Therapeutics Inc
2024/11/1821:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
2024/11/1700:16GlobeNewswire Inc.Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) AmyloidosisNASDAQ:NTLAIntellia Therapeutics Inc
2024/11/0806:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NTLAIntellia Therapeutics Inc
2024/11/0721:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
2024/11/0721:30GlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
2024/11/0606:01GlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
2024/10/3120:30GlobeNewswire Inc.Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024NASDAQ:NTLAIntellia Therapeutics Inc
2024/10/2605:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
2024/10/2421:01GlobeNewswire Inc.Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
2024/10/1020:30GlobeNewswire Inc.Intellia Therapeutics Announces New Date for Upcoming Investor WebcastNASDAQ:NTLAIntellia Therapeutics Inc
2024/10/0720:30GlobeNewswire Inc.Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
2024/10/0506:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
2024/10/0405:01GlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
2024/10/0120:30GlobeNewswire Inc.Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific SessionsNASDAQ:NTLAIntellia Therapeutics Inc
2024/09/1220:30GlobeNewswire Inc.Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific MeetingNASDAQ:NTLAIntellia Therapeutics Inc
2024/09/0405:30GlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
 검색 관련기사 보기:NASDAQ:NTLA

최근 히스토리

BOV
PETRB430W1
PETRB430W1 Ex:41,77
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지